1. Cost-Effectiveness of 2 Models of Pessary Care for Pelvic Organ Prolapse: Findings From the TOPSY Randomized Controlled Trial.
- Author
-
Manoukian, Sarkis, Mason, Helen, Hagen, Suzanne, Kearney, Rohna, Goodman, Kirsteen, Best, Catherine, Elders, Andrew, Melone, Lynn, Dwyer, Lucy, Dembinsky, Melanie, Khunda, Aethele, Guerrero, Karen Lesley, McClurg, Doreen, Norrie, John, Thakar, Ranee, and Bugge, Carol
- Subjects
- *
PELVIC organ prolapse , *PELVIC floor , *COST effectiveness , *QUALITY-adjusted life years , *WOMEN'S health services , *CONTROL (Psychology) , *COST estimates , *ESTIMATES - Abstract
Pelvic organ prolapse is the descent of one or more reproductive organs from their normal position, causing associated negative symptoms. One conservative treatment option is pessary management. This study aimed to to investigate the cost-effectiveness of pessary self-management (SM) when compared with clinic-based care (CBC). A decision analytic model was developed to extend the economic evaluation. A randomized controlled trial with health economic evaluation. The SM group received a 30-minute SM teaching session, information leaflet, 2-week follow-up call, and a local helpline number. The CBC group received routine outpatient pessary appointments, determined by usual practice. The primary outcome for the cost-effectiveness analysis was incremental cost per quality-adjusted life year (QALY), 18 months post-randomization. Uncertainty was handled using nonparametric bootstrap analysis. In addition, a simple decision analytic model was developed using the trial data to extend the analysis over a 5-year period. There was no significant difference in the mean number of QALYs gained between SM and CBC (1.241 vs 1.221), but mean cost was lower for SM (£578 vs £728). The incremental net benefit estimated at a willingness to pay of £20 000 per QALY gained was £564, with an 80.8% probability of cost-effectiveness. The modeling results were consistent with the trial analysis: the incremental net benefit was estimated as £4221, and the probability of SM being cost-effective at 5 years was 69.7%. Results suggest that pessary SM is likely to be cost-effective. The decision analytic model suggests that this result is likely to persist over longer durations. • Women who experience pelvic organ prolapse report discomfort and associated urinary, bowel, and sexual problems with considerable costs and negative impact on quality of life. Pessary self-management (SM) may offer benefits to women and to the health service without increased risk when compared with clinic-based care (CBC). • With pessary SM women receive training to be able to remove and reinsert the pessary themselves at home, thus, by design, offering more personal control and less physical contact with healthcare staff. The aim of the economic evaluation in this study was to investigate health service resources required and cost-effectiveness of pessary SM when compared with CBC at 18 months, from a health sector perspective. • Pessary SM for prolapse is cost-effective when compared with CBC. Decision analytic modeling showed that SM remained a cost-effective option for durations longer than the 18 month trial. SM is an approach that can be used for non-surgical management of prolapse without negatively affecting women's quality of life, which can release scarce resources in a health system under pressure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF